These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1518 related items for PubMed ID: 17369568

  • 1. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
    Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Foà R, Larocca LM.
    J Clin Oncol; 2007 Mar 20; 25(9):1048-53. PubMed ID: 17369568
    [Abstract] [Full Text] [Related]

  • 2. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W.
    Pathol Biol (Paris); 2007 Mar 20; 55(2):92-104. PubMed ID: 16919893
    [Abstract] [Full Text] [Related]

  • 3. Frequency and clinical features of the JAK2 V617F mutation in pediatric patients with sporadic essential thrombocythemia.
    Nakatani T, Imamura T, Ishida H, Wakaizumi K, Yamamoto T, Otabe O, Ishigami T, Adachi S, Morimoto A.
    Pediatr Blood Cancer; 2008 Dec 20; 51(6):802-5. PubMed ID: 18802948
    [Abstract] [Full Text] [Related]

  • 4. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia.
    Tefferi A, Sirhan S, Lasho TL, Schwager SM, Li CY, Dingli D, Wolanskyj AP, Steensma DP, Mesa R, Gilliland DG.
    Br J Haematol; 2005 Oct 20; 131(2):166-71. PubMed ID: 16197445
    [Abstract] [Full Text] [Related]

  • 5. PRV-1 mRNA expression discriminates two types of essential thrombocythemia.
    Griesshammer M, Klippel S, Strunck E, Temerinac S, Mohr U, Heimpel H, Pahl HL.
    Ann Hematol; 2004 Jun 20; 83(6):364-70. PubMed ID: 15034760
    [Abstract] [Full Text] [Related]

  • 6. The effects of hydroxyurea on PRV-1 expression in patients with essential thrombocythemia and polycythemia vera.
    Johansson P, Ricksten A, Wasslavik C, Johansson B, Andréasson B.
    Haematologica; 2004 Oct 20; 89(10):1264-6. PubMed ID: 15477215
    [Abstract] [Full Text] [Related]

  • 7. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S, Michiels JJ.
    Semin Thromb Hemost; 2006 Jun 20; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [Abstract] [Full Text] [Related]

  • 8. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
    Tutaeva V, Misurin AV, Michiels JJ, Rozenberg JM, Sokolova MA, Ivanova VL, Kolosheinova TI, Manakova TE, Levina AA, Semenova EA, Khoroshko ND.
    Hematology; 2007 Dec 20; 12(6):473-9. PubMed ID: 17852451
    [Abstract] [Full Text] [Related]

  • 9. A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood.
    Poodt J, Fijnheer R, Walsh IB, Hermans MH.
    Hematol Oncol; 2006 Dec 20; 24(4):227-33. PubMed ID: 17006961
    [Abstract] [Full Text] [Related]

  • 10. Current evaluation of the clinical, diagnostic, and therapeutic usefulness of prv-1 and c-mpl markers in polycythemia vera and essential thrombocythemia.
    Pahl HL.
    Clin Adv Hematol Oncol; 2004 Apr 20; 2(4):202, 204. PubMed ID: 16163180
    [No Abstract] [Full Text] [Related]

  • 11. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
    Michiels JJ, De Raeve H, Berneman Z, Van Bockstaele D, Hebeda K, Lam K, Schroyens W.
    Semin Thromb Hemost; 2006 Jun 20; 32(4 Pt 2):307-40. PubMed ID: 16810609
    [Abstract] [Full Text] [Related]

  • 12. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ, Berneman Z, Schroyens W, De Raeve H.
    Acta Haematol; 2015 Jun 20; 133(1):36-51. PubMed ID: 25116092
    [Abstract] [Full Text] [Related]

  • 13. Childhood polycythemia vera and essential thrombocythemia: does their pathogenesis overlap with that of adult patients?
    Teofili L, Foà R, Giona F, Larocca LM.
    Haematologica; 2008 Feb 20; 93(2):169-72. PubMed ID: 18245648
    [No Abstract] [Full Text] [Related]

  • 14. [Myeloproliferative diseases caused by JAK2 mutation].
    Nagata K, Shimoda K.
    Rinsho Byori; 2009 Apr 20; 57(4):357-64. PubMed ID: 19489438
    [Abstract] [Full Text] [Related]

  • 15. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W.
    Semin Thromb Hemost; 2006 Apr 20; 32(3):174-207. PubMed ID: 16673274
    [Abstract] [Full Text] [Related]

  • 16. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC.
    Eur J Haematol; 2007 Dec 20; 79(6):508-15. PubMed ID: 17961178
    [Abstract] [Full Text] [Related]

  • 17. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlué J, Büsche G, Kreipe H.
    Exp Hematol; 2009 Oct 20; 37(10):1186-1193.e7. PubMed ID: 19616600
    [Abstract] [Full Text] [Related]

  • 18. Epigenetic control of PRV-1 expression on neutrophils.
    Jelinek J, Li J, Mnjoyan Z, Issa JP, Prchal JT, Afshar-Kharghan V.
    Exp Hematol; 2007 Nov 20; 35(11):1677-83. PubMed ID: 17976520
    [Abstract] [Full Text] [Related]

  • 19. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
    Chao HY, Fan Z, Zhang R, Shen YM, Chen W, Fei HR, Zhu ZL, Feng YF, Chen ZX, Xue YQ.
    Zhonghua Zhong Liu Za Zhi; 2009 Jul 20; 31(7):510-4. PubMed ID: 19950698
    [Abstract] [Full Text] [Related]

  • 20. The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia.
    Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Leone G, Foà R, Larocca LM.
    Blood; 2007 Nov 01; 110(9):3384-6. PubMed ID: 17644735
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 76.